Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative RT and TMZ in Glioblastoma
NCT03480867Phase 1Withdrawn
- Sponsor
- McGill University Health Centre
- Start
- Mar 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by McGill University Health Centre. Primary endpoint: Toxicity of the regimen at 1 year. Planned start Mar 2017; status: withdrawn.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03480867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480867.